Eli Lilly has become the most valuable pharmaceutical company on the planet for one reason: Americans can’t stop wanting to lose weight. With Mounjaro and Zepbound generating over $10 billion per quarter and an oral obesity pill waiting in the FDA queue, LLY stock has transformed from sleepy Indiana pharma to trillion-dollar growth story. Track every tick in real time below.
Eli Lilly (LLY) Live Stock Chart
The GLP-1 Juggernaut: How Lilly Became A Trillion-Dollar Company
A decade ago, Eli Lilly was a respectable but unexciting pharmaceutical company best known for antidepressants and insulin. Today it’s worth more than Johnson & Johnson, Pfizer, and Merck. The transformation came down to two drugs: Mounjaro (for diabetes) and Zepbound (for obesity), both powered by tirzepatide, a molecule that activates two gut hormones simultaneously.
The numbers are staggering. In Q3 2025, Lilly reported $17.6 billion in revenue, a 54% year-over-year surge that demolished Wall Street expectations by $1.6 billion. Mounjaro generated $6.5 billion that quarter. Zepbound added another $3.6 billion. Together, that’s $10.1 billion from a single molecule that didn’t exist on the market three years ago.
What makes tirzepatide different from Novo Nordisk’s semaglutide (the active ingredient in Ozempic and Wegovy)? It’s a dual-agonist that targets both GLP-1 and GIP receptors, compared to semaglutide’s single GLP-1 mechanism. In head-to-head trials, the difference showed: Zepbound achieved 20.2% average weight loss at 72 weeks, compared to Wegovy’s 13.7%. That’s the kind of data that wins market share.
Key LLY Stock Metrics And Fundamentals
Lilly trades at valuations that would make traditional pharma investors faint. With a market capitalization hovering around $1 trillion and a P/E ratio above 50, LLY is priced like a tech growth stock, not a 150-year-old drug company founded in Indianapolis. The premium reflects what analysts see ahead: revenue projected to reach $94 billion by 2027, more than doubling from 2024’s $45 billion.
The stock reached an all-time high of $1,109.94 on November 25, 2025, before pulling back into the $1,050-$1,090 range heading into 2026. Its 52-week trading range spans from $623.78 to $1,133.95, reflecting the volatility that comes with being a momentum-driven healthcare name. Analysts maintain a consensus “Strong Buy” rating with an average price target around $1,161, suggesting modest upside from current levels.
For income investors, Lilly pays a quarterly dividend of $1.73 per share, with an ex-dividend date of February 13, 2026. But with a yield under 1%, nobody owns LLY for the dividend. They own it for the growth story.
The Trump Administration Deal Changes Everything
In January 2026, President Trump announced landmark drug pricing agreements with both Eli Lilly and Novo Nordisk. The deal unlocks access to nearly 40 million Americans on government insurance who previously couldn’t afford GLP-1 drugs for obesity. Starting April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound through a new multi-dose pen formulation.
The agreement also covers orforglipron, Lilly’s oral GLP-1 pill currently awaiting FDA approval. If approved, it will be priced at $149 for the lowest dose through LillyDirect, Lilly’s direct-to-patient pharmacy channel. Medicare and Medicaid prices for these drugs will drop to $245 monthly, down from list prices exceeding $1,000.
For investors, this creates an interesting dynamic. Lower per-unit prices in exchange for dramatically expanded volume. The question is whether Lilly’s manufacturing capacity can keep up with potentially exponential demand growth. The company has committed over $50 billion to U.S. manufacturing expansion since 2020, including new facilities in Texas, Indiana, and Puerto Rico.
The Pipeline: What’s Coming After Mounjaro And Zepbound
Lilly isn’t resting on tirzepatide’s success. The company has multiple next-generation obesity treatments in development that could extend its lead over Novo Nordisk.
Orforglipron is the nearest-term catalyst. This once-daily oral GLP-1 pill would eliminate the weekly injection that some patients find inconvenient. Lilly has applied for the FDA’s Commissioner’s National Priority Voucher, which could accelerate approval from the typical 10-12 months down to 1-2 months. Phase 3 data showed patients switching from injectable Wegovy to oral orforglipron maintained nearly all their weight loss, with an average difference of just 0.9 kg.
Retatrutide is the company’s next-generation injectable. It targets three hormones (GLP-1, GIP, and glucagon) instead of two, and early results are remarkable. In Phase 3 trials, patients lost nearly 29% of their body weight on average after 16 months. That’s approximately 10 percentage points more than current market leaders. The catch: an 18.2% dropout rate suggests side effects may be more intense. Lilly expects to complete additional trials in 2026 and could file for FDA approval this year.
Beyond obesity, Lilly is running studies on tirzepatide for chronic kidney disease and cardiovascular outcomes. Zepbound already won FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity. The company is methodically expanding the conditions these drugs can treat, each approval adding to the total addressable market.
The Novo Nordisk Rivalry Intensifies
Eli Lilly and Novo Nordisk are locked in what may become the most consequential pharmaceutical rivalry of the decade. Novo fired the opening shot by launching the first oral Wegovy pill in January 2026, recording nearly 20,000 prescriptions in its first week. The Danish company priced it aggressively at $149-$299 per month, undercutting expectations.
But Lilly holds the clinical advantage. In head-to-head data, tirzepatide consistently outperforms semaglutide on weight loss and glycemic control. Zepbound holds 71% of new U.S. obesity prescriptions. And Lilly’s orforglipron showed it could beat Novo’s semaglutide in reducing A1C for type 2 diabetes patients.
Both companies are racing to file data for new indications, conduct head-to-head trials, and expand manufacturing capacity. For investors, this competition is a feature, not a bug. The overall GLP-1 market is projected to exceed $150 billion, leaving room for both companies to grow even as they fight for share.
What Could Go Wrong: Risks To The Bull Case
At a $1 trillion valuation, a lot of good news is already priced in. Here’s what keeps Lilly bulls awake at night:
PBM exclusions: When CVS Caremark dropped Zepbound from certain formularies in July 2025, about 10% of Zepbound patients switched to competitors. Lilly navigated that exclusion well, but if multiple large pharmacy benefit managers adopt similar stances simultaneously, pricing power could face real constraints.
Manufacturing execution: Lilly has announced over $50 billion in U.S. manufacturing expansion, but building pharmaceutical capacity is notoriously difficult. Delays or quality issues at new facilities could limit the company’s ability to capture demand.
Compounding competition: Telehealth companies like Hims and Ro have offered compounded versions of GLP-1 drugs at steep discounts. While the FDA has moved to restrict this practice, the regulatory landscape remains uncertain.
Valuation compression: Lilly trades at 50+ times forward earnings, a premium that assumes continued hypergrowth. Any disappointment in sales, pipeline setbacks, or broader market rotation away from growth stocks could trigger sharp corrections.
Upcoming Catalysts To Watch
Lilly’s next quarterly earnings report is scheduled for February 5, 2026. Analysts expect earnings per share of $7.50, continuing the streak of strong beats. Beyond earnings, watch for:
Orforglipron FDA decision, potentially accelerated by the priority voucher. The voluntary Medicare GLP-1 payment demonstration beginning in July 2026. Phase 3 results from Novo Nordisk’s head-to-head CagriSema study comparing their combination drug against tirzepatide, expected in Q1 2026. And continued updates on retatrutide trials throughout the year.
Technical Analysis: Reading The LLY Chart
LLY established a major support zone around $780-$800 during its summer 2025 pullback, then rallied to all-time highs above $1,100 by November. The stock has consolidated in the $1,050-$1,090 range heading into 2026, digesting gains while the broader market assesses whether the GLP-1 growth story justifies current valuations.
The chart above includes Bollinger Bands and RSI indicators. Watch for RSI readings above 70 as potential overbought signals, though momentum stocks can stay overbought for extended periods during strong trends. A break above the November highs around $1,110 would signal bullish continuation, while a drop below $1,000 could indicate a deeper correction is underway.
Volume patterns matter for a stock this size. Heavy volume on up days confirms institutional accumulation, while distribution days (down moves on high volume) may signal smart money rotating out.
Frequently Asked Questions About LLY Stock
What Is Eli Lilly’s Current Stock Price?
Eli Lilly (NYSE: LLY) trades around $1,065-$1,085 as of late January 2026. Use the live chart above for real-time pricing during market hours.
Why Has LLY Stock Risen So Much?
The surge is driven primarily by Mounjaro and Zepbound, GLP-1 drugs that have generated over $10 billion per quarter. The obesity and diabetes treatment market has proven larger than almost anyone predicted, and Lilly’s tirzepatide molecule has outperformed competitors in clinical trials.
What Is Eli Lilly’s Market Cap?
Approximately $1 trillion, making it the most valuable pharmaceutical company in the world. This valuation briefly exceeded during the November 2025 peak before consolidating.
When Does Eli Lilly Report Earnings?
Lilly’s next quarterly earnings report is scheduled for February 5, 2026. The company typically releases results before market open with a conference call the same morning.
Does Eli Lilly Pay A Dividend?
Yes. Lilly pays a quarterly dividend of $1.73 per share, with the next ex-dividend date on February 13, 2026. However, the yield is under 1%, making it primarily a growth investment rather than an income play.
What Is The Difference Between Mounjaro And Zepbound?
Both contain the same active ingredient, tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity and weight management (as well as obstructive sleep apnea). Different FDA approvals and insurance coverage, same drug.
How Does Eli Lilly Compare To Novo Nordisk?
Both dominate the GLP-1 market, but with different molecules. Lilly’s tirzepatide is a dual-agonist targeting GLP-1 and GIP, while Novo’s semaglutide targets only GLP-1. Head-to-head trials have favored tirzepatide for weight loss, though Novo has broader global market presence.
What Is Orforglipron?
Lilly’s oral GLP-1 pill currently awaiting FDA approval. It would allow patients to take a daily pill instead of weekly injections, potentially expanding the addressable market to people who avoid needles.
Is LLY Stock A Good Investment?
Analysts rate LLY a consensus “Strong Buy” with price targets averaging around $1,161. However, the stock trades at premium valuations that require continued hypergrowth to justify. Consider your risk tolerance and investment timeline before buying any stock at historically high multiples.
Where Can I Watch LLY Stock In Real Time?
The live TradingView chart at the top of this page updates continuously during market hours with 5-minute candlesticks, Bollinger Bands, and RSI indicators. Bookmark this page for quick access whenever you need to check Lilly’s price action.